The Carney Centre for Pharmacogenomics is a collaboration between research groups based at the University of Otago, Christchurch.
Together, we span a wide range of clinical, pharmacological and genetic expertise. As a result we have a strongly collaborative, multidisciplinary approach to pharmacogenomic research.
Our current research programmes focus on several aspects of pharmacogenetics, pharmacogenomics and related topics. For example, we are studying:
- Potential genetic factors underlying serious adverse reactions, or unusual responses to drugs
- Genome-wide gene expression effects of the mood stabiliser drug sodium valproate, in a brain cell line
- Epigenetic effects of drugs
- Molecular basis of micronutrient treatment in mental disorders
We use a range of methods for these projects, including DNA sequence analysis of specific pharmacogenes, application of genome-wide methods such as whole exome and whole genome sequencing, as well as RNA-sequencing, methylome analysis, and application of novel technologies such as nanopore DNA sequencing.
The Carney Centre is named in honour of our benefactors, the Jim and Mary Carney Charitable Trust
We are investigating how genetic make-up may contribute to adverse reactions to drugs
Kim Ton is developing a genetic screening test to identify those at a higher risk of serious drug reactions